Summary by Moomoo AI
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on March 11, 2024, that the U.S. Patent and Trademark Office (USPTO) has issued a new patent for Talicia, their all-in-one treatment for Helicobacter pylori (H. pylori) infection. The patent, which extends protection for Talicia until February 12, 2034, supports the company's existing intellectual property portfolio, including composition of matter patents and FDA-granted data exclusivities under the GAIN QIDP designation and section 505(b)(2). Talicia is the only FDA-approved therapy containing rifabutin for H. pylori eradication and is the leading branded first-line therapy prescribed by U.S. gastroenterologists. The infection affects approximately 35% of the U.S. adult population. The new patent is expected to bolster Talicia's market exclusivity and strengthen RedHill's commercial position. The announcement also highlighted Talicia's optimized antibiotic resistance profile and its pivotal Phase 3 study results, which showed an 84% eradication rate of H. pylori. RedHill Biopharma focuses on gastrointestinal and infectious diseases and promotes other gastrointestinal drugs alongside Talicia.